Health

Results: 2617-2628 of 8203

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

PR Newswire associated0

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

TRI Launches Major Overhaul of OPRA-CM to Unlock the Full Potential of Centralized Monitoring in Clinical Trials

Louis Denis, MD, Chief Medical Officer, Byondis

Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors

PR Newswire associated0

Sixth Global Pharma Company Selects LifeSphere NavaX for GenAI-Driven Case Processing

PR Newswire associated0

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer

PR Newswire associated0

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Calm Health Expands Globally, Starting with UK and Canada

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing cancer cells